Revenue and gross margin have trended down from $190.8M and 43.6% in 2024Q2 to $117.9M and 34.3% in 2026Q3, with operating margin turning deeply negative (-162.7%) in 2026Q1 due to impairment-driven losses.
MGP Ingredients, Inc. (MGPI) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Jun'11 | Jun'10 | Jun'09 | Jun'08 | Jul'07 | Jun'06 | Jun'05 | Jun'04 | Jun'03 | Jun'02 | Jun'01 | Jun'00 | Jun'99 | Jun'98 | Jun'97 | Jun'96 |
|---|
| Sales/Revenue | 487.01M | 536.38M | 703.63M | 836.52M | 782.36M | 626.72M | 395.52M | 362.75M | 376.09M | 347.45M | 318.26M | 327.6M | 313.4M | 323.26M | 334.33M | 247.91M | 201.97M | 275.98M | 392.89M | 367.99M | 322.48M | 275.18M | 270.67M | 192.37M | 214.53M | 229.24M | 231.88M | 216.1M | 223.3M | 224.7M | 194.6M |
| Revenue Growth % | -15.87% | -23.77% | -15.89% | 6.92% | 24.83% | 58.45% | 9.04% | -3.55% | 8.24% | 9.17% | -2.85% | 4.53% | -3.05% | -3.31% | 34.86% | 22.75% | -26.82% | -29.76% | 6.77% | 14.11% | 17.19% | 1.66% | 40.7% | -10.33% | -6.42% | -1.14% | 7.3% | -3.22% | -0.62% | 15.47% | 7.93% |
| Cost of Goods Sold | 318.24M | 336.97M | 417.31M | 531.81M | 529.05M | 427.75M | 296.71M | 286.21M | 292.49M | 271.43M | 252.98M | 269.07M | 284.97M | 302.02M | 309.31M | 225.04M | 171.43M | 310.08M | 388.66M | 321.94M | 277.26M | 249.94M | 245.77M | 202.11M | 193.32M | 212.06M | 197.46M | 187M | 200.6M | 199.7M | 176.3M |
| COGS % of Revenue | - | 62.82% | 59.31% | 63.57% | 67.62% | 68.25% | 75.02% | 78.9% | 77.77% | 78.12% | 79.49% | 82.13% | 90.93% | 93.43% | 92.52% | 90.77% | 84.88% | 112.36% | 98.92% | 87.49% | 85.98% | 90.83% | 90.8% | 105.06% | 90.12% | 92.5% | 85.16% | 86.53% | 89.83% | 88.87% | 90.6% |
| Gross Profit | 168.77M | 199.41M | 286.32M | 304.71M | 253.31M | 198.97M | 98.81M | 76.53M | 83.6M | 76.02M | 65.28M | 58.53M | 28.43M | 21.24M | 25.02M | 22.88M | 30.54M | -34.1M | 4.23M | 46.05M | 45.21M | 25.24M | 24.91M | -9.74M | 21.2M | 17.18M | 34.42M | 29.1M | 22.7M | 25M | 18.3M |
| Gross Margin % | 34.65% | 37.18% | 40.69% | 36.43% | 32.38% | 31.75% | 24.98% | 21.1% | 22.23% | 21.88% | 20.51% | 17.87% | 9.07% | 6.57% | 7.48% | 9.23% | 15.12% | -12.36% | 1.08% | 12.51% | 14.02% | 9.17% | 9.2% | -5.06% | 9.88% | 7.5% | 14.84% | 13.47% | 10.17% | 11.13% | 9.4% |
| Gross Profit Growth % | - | -30.35% | -6.04% | 20.29% | 27.31% | 101.37% | 29.1% | -8.45% | 9.98% | 16.44% | 11.53% | 105.88% | 33.86% | -15.12% | 9.38% | -25.1% | 189.57% | -906% | -90.81% | 1.86% | 79.13% | 1.34% | 355.72% | -145.94% | 23.4% | -50.07% | 18.27% | 28.19% | -9.2% | 36.61% | -38.8% |
| Operating Expenses | 445.36M | 294.02M | 211.89M | 156.1M | 104.34M | 72.6M | 44.56M | 29.29M | 33.45M | 33.11M | 23.31M | 25.68M | 20.1M | 26.44M | 25.97M | 21.98M | 23.29M | 26.09M | 33.88M | 18.89M | 22.84M | 18.61M | 9.62M | -3.79M | 9.82M | 13.54M | 25.62M | 25.5M | 25.3M | 23.2M | 22.9M |
| OpEx % of Revenue | - | 54.82% | 30.11% | 18.66% | 13.34% | 11.58% | 11.27% | 8.07% | 8.89% | 9.53% | 7.32% | 7.84% | 6.41% | 8.18% | 7.77% | 8.87% | 11.53% | 9.46% | 8.62% | 5.13% | 7.08% | 6.76% | 3.55% | -1.97% | 4.58% | 5.91% | 11.05% | 11.8% | 11.33% | 10.32% | 11.77% |
| Selling, General & Admin | 138.18M | 115.9M | 121.9M | 129.61M | 104.34M | 88.93M | 44.56M | 29.29M | 33.45M | 33.11M | 26.69M | 25.68M | 20.1M | 26.2M | 26.54M | 21.16M | 20.71M | 21.4M | 24.23M | 20.32M | 23.81M | 19.32M | 20.34M | 13.62M | 14.69M | 13.54M | 12.11M | 11.9M | 11.4M | 9.2M | 9M |
| SG&A % of Revenue | - | 21.61% | 17.32% | 15.49% | 13.34% | 14.19% | 11.27% | 8.07% | 8.89% | 9.53% | 8.39% | 7.84% | 6.41% | 8.11% | 7.94% | 8.53% | 10.25% | 7.75% | 6.17% | 5.52% | 7.38% | 7.02% | 7.51% | 7.08% | 6.85% | 5.91% | 5.22% | 5.51% | 5.11% | 4.09% | 4.62% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 916K | 748K | 1.62M | 2.47M | 2.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | 0.29% | 0.23% | 0.52% | 0.76% | 0.7% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 1.51M | 178.12M | 89.99M | 26.49M | 0 | -16.32M | 0 | 0 | 0 | 0 | 3.38M | 0 | -1K | -236K | 2K | 826K | 2.58M | 4.69M | 9.65M | -1.43M | -968K | -707K | -10.72M | -17.4M | -4.87M | 0 | 13.52M | 13.6M | 13.9M | 14M | 13.9M |
| Operating Income | -276.59M | -94.61M | 74.43M | 148.61M | 148.97M | 126.36M | 54.24M | 47.24M | 50.15M | 42.91M | 41.98M | 32.85M | 16.62M | -5.2M | -944K | 645K | 7.25M | -79.01M | -29.65M | 27.16M | 22.37M | 6.63M | 15.29M | -5.95M | 11.38M | 3.64M | 8.79M | 3.6M | -2.6M | 1.8M | -4.6M |
| Operating Margin % | -56.79% | -17.64% | 10.58% | 17.77% | 19.04% | 20.16% | 13.71% | 13.02% | 13.33% | 12.35% | 13.19% | 10.03% | 5.3% | -1.61% | -0.28% | 0.26% | 3.59% | -28.63% | -7.55% | 7.38% | 6.94% | 2.41% | 5.65% | -3.09% | 5.3% | 1.59% | 3.79% | 1.67% | -1.16% | 0.8% | -2.36% |
| Operating Income Growth % | - | -227.13% | -49.92% | -0.24% | 17.89% | 132.97% | 14.82% | -5.79% | 16.87% | 2.23% | 27.78% | 97.67% | 419.66% | -450.74% | -246.36% | -91.11% | 109.18% | -166.47% | -209.17% | 21.41% | 237.41% | -56.63% | 356.77% | -152.32% | 212.78% | -58.63% | 144.25% | 238.46% | -244.44% | 139.13% | -143.4% |
| EBITDA | -251.26M | -70.53M | 96.42M | 170.73M | 170.42M | 145.46M | 67.2M | 58.81M | 61.51M | 54.22M | 53.23M | 45.23M | 28.94M | 6.81M | 10.62M | 9.49M | 15.89M | -67.06M | -14.48M | 41.63M | 35.02M | 22.64M | 30.48M | 8.4M | 25.69M | 17.27M | 22.31M | 17.2M | 11.3M | 15.8M | 9.3M |
| EBITDA Margin % | -51.59% | -13.15% | 13.7% | 20.41% | 21.78% | 23.21% | 16.99% | 16.21% | 16.36% | 15.6% | 16.72% | 13.81% | 9.24% | 2.11% | 3.18% | 3.83% | 7.87% | -24.3% | -3.69% | 11.31% | 10.86% | 8.23% | 11.26% | 4.37% | 11.97% | 7.53% | 9.62% | 7.96% | 5.06% | 7.03% | 4.78% |
| EBITDA Growth % | -846.45% | -173.15% | -43.53% | 0.18% | 17.16% | 116.44% | 14.26% | -4.38% | 13.45% | 1.86% | 17.68% | 56.27% | 325.02% | -35.9% | 11.97% | -40.27% | 123.69% | -363.2% | -134.78% | 18.85% | 54.72% | -25.74% | 262.92% | -67.3% | 48.78% | -22.61% | 29.7% | 52.21% | -28.48% | 69.89% | -51.81% |
| D&A (Non-Cash Add-back) | 25.33M | 24.09M | 21.99M | 22.11M | 21.45M | 19.09M | 12.96M | 11.57M | 11.36M | 11.31M | 11.25M | 12.38M | 12.32M | 12.01M | 11.57M | 8.84M | 8.63M | 11.95M | 15.17M | 14.47M | 12.65M | 16.01M | 15.2M | 14.35M | 14.31M | 13.63M | 13.52M | 13.6M | 13.9M | 14M | 13.9M |
| EBIT | -277.85M | -93.31M | 76.88M | 148.39M | 145.62M | 125.13M | 54.24M | 47.24M | 50.15M | 42.91M | 38.59M | 32.85M | 7.44M | -5.4M | 2.81M | 2.99M | -887K | 5.73M | -79.01M | -25.35M | 27.16M | 22.37M | 6.63M | 15.29M | -5.95M | 11.38M | 3.64M | 8.79M | 3.6M | -2.6M | 1.8M |
| Net Interest Income | -9.22M | -7.04M | -8.44M | -6.65M | -5.45M | -4.04M | -2.27M | -1.3M | -1.17M | -1.18M | -1.29M | -534K | -816K | -1.12M | -868K | 0 | -358K | -1.76M | -2.9M | -1.49M | -964K | -1.48M | -1.39M | -1.09M | 0 | -1.24M | -1.35M | 0 | 0 | 0 | -2.6M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.22M | 7.04M | 8.44M | 6.65M | 5.45M | 4.04M | 2.27M | 1.3M | 1.17M | 1.18M | 1.29M | 534K | 816K | 1.12M | 870K | 358K | 1.76M | 2.9M | 1.49M | 964K | 1.48M | 1.39M | 1.09M | 1.09M | 1.24M | 1.35M | 1.35M | 1.1M | 400K | 2.6M | 2.6M |
| Other Income/Expense | -10.48M | -5.74M | -5.98M | -6.87M | -8.79M | -5.27M | -1.64M | -1.3M | -1.17M | 9.85M | 2.74M | 5.57M | 9.32M | -1.32M | 2.89M | 1.47M | -1.89M | -3.29M | -2.9M | 6.06M | 5.32M | -1.34M | 362K | 362K | 14.47M | -1.01M | -4.4M | 4.48M | 4.7M | -1.1M | 4.8M |
| Pretax Income | -287.07M | -100.35M | 68.44M | 141.75M | 140.17M | 121.1M | 52.6M | 45.94M | 48.98M | 52.76M | 44.72M | 38.42M | 25.94M | -6.52M | 1.94M | -1.25M | 3.97M | -81.91M | -23.59M | 27.69M | 21.02M | 6.13M | 15.65M | 8.52M | 10.37M | 4.4M | 8.08M | 2.1M | -3.7M | 200K | -5.6M |
| Pretax Margin % | -58.95% | -18.71% | 9.73% | 16.94% | 17.92% | 19.32% | 13.3% | 12.66% | 13.02% | 15.18% | 14.05% | 11.73% | 8.28% | -2.02% | 0.58% | -0.5% | 1.97% | -29.68% | -6% | 7.52% | 6.52% | 2.23% | 5.78% | 4.43% | 4.83% | 1.92% | 3.49% | 0.97% | -1.66% | 0.09% | -2.88% |
| Income Tax | -36.53M | 7.48M | 33.98M | 34.62M | 31.3M | 30.28M | 12.26M | 7.14M | 11.7M | 10.94M | 13.53M | 12.23M | 2.27M | -714K | 318K | 68K | -4.77M | -12.79M | -11.85M | 9.99M | 7.03M | 2.12M | 6.18M | 3.37M | 4.11M | 1.74M | 3.19M | 800K | -1.5M | 100K | -2.2M |
| Effective Tax Rate % | 12.72% | -7.46% | 49.64% | 24.42% | 22.33% | 25% | 23.3% | 15.55% | 23.88% | 20.73% | 30.26% | 31.83% | 8.73% | 10.95% | 16.37% | -5.46% | -120.1% | 15.61% | 50.23% | 36.08% | 33.44% | 34.65% | 39.5% | 39.51% | 39.63% | 39.5% | 39.5% | 38.1% | 40.54% | 50% | 39.29% |
| Net Income | -250.54M | -107.81M | 34.66M | 107.47M | 109.46M | 91.31M | 40.34M | 38.79M | 37.28M | 41.82M | 31.18M | 26.19M | 23.68M | -4.93M | 1.62M | -1.31M | 8.74M | -69.12M | -11.74M | 17.7M | 13.99M | 4M | 9.47M | 5.15M | 6.26M | 2.66M | 4.89M | 1.3M | -2.2M | 100K | -3.4M |
| Net Margin % | -51.44% | -20.1% | 4.93% | 12.85% | 13.99% | 14.57% | 10.2% | 10.69% | 9.91% | 12.04% | 9.8% | 7.99% | 7.55% | -1.52% | 0.49% | -0.53% | 4.33% | -25.05% | -2.99% | 4.81% | 4.34% | 1.46% | 3.5% | 2.68% | 2.92% | 1.16% | 2.11% | 0.6% | -0.99% | 0.04% | -1.75% |
| Net Income Growth % | -1555.04% | -411.02% | -67.75% | -1.82% | 19.88% | 126.32% | 4% | 4.05% | -10.85% | 34.12% | 19.06% | 10.63% | 580.32% | -403.51% | 223.69% | -115.03% | 112.64% | -488.68% | -166.35% | 26.46% | 249.53% | -57.71% | 83.7% | -17.65% | 135.3% | -45.6% | 276.15% | 159.09% | -2300% | 102.94% | -203.03% |
| Net Income (Continuing) | -250.54M | -107.81M | 34.47M | 107.13M | 108.87M | 90.82M | 40.34M | 38.79M | 37.28M | 41.82M | 31.18M | 26.19M | 23.68M | -5.81M | 1.62M | 18.94M | -1.31M | 8.74M | -69.12M | -11.74M | 17.7M | 13.99M | 4M | 9.47M | 5.15M | 6.26M | 2.66M | 4.89M | 1.3M | -2.2M | 100K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 878K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | -1.65M | -1.62M | -1.43M | -1.08M | -490K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -11.68 | -4.99 | 1.56 | 4.80 | 4.92 | 4.32 | 2.37 | 2.27 | 2.21 | 2.44 | 1.82 | 1.48 | 1.32 | -0.29 | 0.09 | -0.08 | 0.51 | -4.17 | -0.70 | 1.05 | 0.83 | 0.24 | 0.59 | 0.33 | 0.38 | 0.16 | 0.24 | 0.07 | -0.11 | 0.00 | -0.18 |
| EPS Growth % | -1638.81% | -419.87% | -67.5% | -2.44% | 13.89% | 82.28% | 4.41% | 2.71% | -9.43% | 34.07% | 22.97% | 12.12% | 555.17% | -422.22% | 214.65% | -115.39% | 112.23% | -495.71% | -166.67% | 26.51% | 245.83% | -59.32% | 78.79% | -13.16% | 137.5% | -33.33% | 269.23% | 159.09% | - | 102.44% | -205.88% |
| EPS (Basic) | - | -4.99 | 1.56 | 4.82 | 4.94 | 4.37 | 2.37 | 2.27 | 2.21 | 2.44 | 1.82 | 1.48 | 1.32 | -0.29 | 0.09 | -0.08 | 0.52 | -4.17 | -0.71 | 1.08 | 0.87 | 0.25 | 0.61 | 0.33 | 0.38 | 0.16 | 0.27 | 0.07 | -0.11 | 0.01 | -0.18 |
| Diluted Shares Outstanding | 21.46M | 21.36M | 22.02M | 22.17M | 22.05M | 20.98M | 16.94M | 17.01M | 16.87M | 16.75M | 16.64M | 17.12M | 17.31M | 17.07M | 16.95M | 16.73M | 17.08M | 16.59M | 16.77M | 16.86M | 16.86M | 16.36M | 16.05M | 15.62M | 16.3M | 16.63M | 20M | 20M | 20M | 22.5M | 19.43M |
| Basic Shares Outstanding | 21.46M | 21.36M | 22.02M | 22.06M | 22M | 20.72M | 16.94M | 17.01M | 16.87M | 16.75M | 16.64M | 17.12M | 17.31M | 17.07M | 16.95M | 16.73M | 16.66M | 16.59M | 16.54M | 16.39M | 16.11M | 15.97M | 15.52M | 15.62M | 16.26M | 16.63M | 18.11M | 20M | 19.13M | 20M | 19.43M |
| Dividend Payout Ratio | - | - | 30.67% | 9.93% | 9.73% | 10.97% | 20.29% | 17.67% | 14.75% | 41.56% | 6.63% | 4.15% | 3.83% | - | 56.28% | - | 10.2% | - | - | 23.92% | 35.98% | 61.99% | 25.68% | 22.27% | - | 45.9% | 17.48% | - | - | - | - |
Quick answers to the most common questions about buying MGPI stock.
For fiscal year 2025, MGP Ingredients, Inc. (MGPI) reported total revenue of $536.4M. This represents a 175.6% increase compared to $194.6M in 1996.
MGP Ingredients, Inc. (MGPI) reported a net loss of $107.8M for the fiscal year ending 2025.
MGP Ingredients, Inc. (MGPI) reported an operating income of $-94.6M, resulting in an operating profit margin of -17.6%. This margin reflects the operational efficiency of the business before interest and taxes.
MGP Ingredients, Inc. (MGPI) generated $199.4M in gross profit for the year, representing a gross profit margin of 37.2%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Volatile impairment-driven losses
Metrics are mathematically derived from official filings.
Revenue Contracting Across Consecutive Quarters
Based on reported quarterly figures, MGPI's revenue declined from $190.8M in 2024Q2 to $117.9M in 2026Q3, with year-over-year declines of roughly 9% to 24% across most recent periods.
The sustained year-over-year revenue contraction suggests softening demand or pricing pressure in MGPI's core spirits and ingredients businesses rather than a single transitory event. The data does not disaggregate volume from price, so it is unclear whether the decline reflects lower shipments or weaker realized pricing, which warrants further investigation. Investors should monitor whether the recent 2026Q3 rate of decline moderates, as continued contraction would challenge the durability of the revenue base.
Gross Margin Compressing From Peak Levels
Reported gross margin fell from 43.6% in 2024Q2 to 34.3% in 2026Q3, a decline of roughly nine percentage points that exceeds the drift seen at peers such as SAM at 45.6%.
The gross margin compression indicates that MGPI's cost of goods sold has risen faster than its selling prices, consistent with reduced pricing power or unfavorable input and absorption dynamics. Relative to The Boston Beer Company's 45.6% gross margin, MGPI now sits at a meaningful discount, which may point to a less differentiated product mix. Margin recovery would be the key indicator to watch for whether the cost pressure is cyclical or structural.
Reported Earnings Distorted by Impairment Charges
MGPI's 2026Q1 operating loss of $173.2M and net loss of $134.8M, against revenue of $106.4M, appear driven by non-recurring charges rather than core operating performance, with EPS swinging to -$6.30.
The magnitude of the 2026Q1 and 2025Q4 losses relative to revenue suggests large non-cash or non-operating items, though the supplied data does not itemize them, so their nature cannot be confirmed. Excluding these periods, quarterly operating margins have generally remained positive in the mid-single to mid-teens range. Investors should treat reported EPS with caution and focus on normalized operating income until the composition of these charges is clarified.
Operating Deleverage as Gross Profit Falls
Gross profit declined from $83.2M in 2024Q2 to $40.5M in 2026Q3 while SG&A remained comparatively stable near $26M to $35M, indicating that fixed overhead is absorbing a larger share of a shrinking gross profit base.
Because SG&A has not contracted in step with gross profit, operating margin has been compressed more sharply than gross margin alone would imply. This pattern suggests limited near-term ability to flex the cost base in response to the revenue decline. Management's ability to reduce overhead without impairing commercial capacity is a key question for future quarters.
Bear Case Centers on Recurring Write-Downs
The strongest bear argument is that repeated large losses in 2025Q4 and 2026Q1 may reflect recurring asset write-downs, with the peer comparison showing CODI operating at a 2.3% margin and negative net margin.
Short-sellers would likely argue that a pattern of large charges against a declining revenue base signals impaired asset values that may not be fully captured in the reported figures, though this cannot be confirmed from the supplied data. The absence of reported R&D and minimal stock-based compensation simplify the earnings picture but do not resolve the question of charge recurrence. Continued revenue contraction combined with the possibility of further impairments would warrant a more cautious view of the income statement trajectory.